| Daniel L Bonifacio, DO | |
|
1200 Sixth St, Suite 200, Traverse City, MI 49684-2369 | |
| (231) 935-5800 | |
| (231) 935-5799 |
| Full Name | Daniel L Bonifacio |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 1200 Sixth St, Traverse City, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033104880 | NPI | - | NPPES |
| 4204742 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 5101011505 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Daniel L Bonifacio, DO 2891 Momentum Pl, Chicago, IL 60689-5328 Ph: (231) 935-6080 | Daniel L Bonifacio, DO 1200 Sixth St, Suite 200, Traverse City, MI 49684-2369 Ph: (231) 935-5800 |
News Archive
A study published today in Nicotine & Tobacco Research demonstrates in a carefully controlled series of studies that the self-administration of nicotine by rats suppresses body weight gain independent of food intake.
Vasomedical, Inc. today announced that its subsidiary, Vaso Diagnostics Inc. d/b/a Vaso Healthcare, has signed a sales representative agreement with GE Healthcare, the healthcare business unit of GE, for the sale of select GE Healthcare Diagnostic Imaging products. Under the Agreement, Vaso Healthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and District of Columbia.
S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).
Vasomedical, Inc., a global provider of medical devices, today announced financial results of the three months ended November 30, 2010. Vasomedical is a world leader in the noninvasive treatment of cardiovascular diseases.
A breakthrough in genetic research has uncovered the defect behind a rare hereditary children's disease that inhibits the body's ability to break down vitamin D. This discovery has led researchers to develop the first genetic and biochemical tests that positively identify the disease.
› Verified 4 days ago
John P Milliken, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 224 Circle Dr, Traverse City, MI 49684 Phone: 231-935-0525 Fax: 231-935-0529 | |
Dr. David R Hendricks, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 153 1/2 E Front St, Traverse City, MI 49684 Phone: 231-941-6670 Fax: 231-941-6675 | |
Dr. Jill Elizabeth Vollbrecht, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5015 N Royal Dr, Traverse City, MI 49684 Phone: 231-935-0850 Fax: 231-935-0850 | |
Dr. Katrina Marie Lawrence-wolff, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3537 W Front St Ste A, Traverse City, MI 49684 Phone: 231-935-8330 Fax: 231-935-3437 | |
Steven M. Lamie, M. D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3537 W Front St, Suite I, Traverse City, MI 49684 Phone: 231-935-8950 Fax: 231-935-8868 | |
Anne M Hepner, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Sixth St, Suite 200, Traverse City, MI 49684 Phone: 231-935-5800 Fax: 231-935-5799 | |
Mark V Galan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 208, Traverse City, MI 49684 Phone: 231-935-5710 Fax: 231-935-9045 |